Genetic or pharmacological inhibition of ACAT1 has been shown to reduce LD burden, suppress pro-inflammatory cytokine release, and protect dopaminergic neurons in experimental models of PD and AD (Huynh et al., 2024; Sun et al., 2025; Valencia-Olvera et al., 2023). This evidence concerns the gene ACAT1 and Parkinson disease.